Nkarta is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
NKX101 and NKX019 Phase 1 Data – Company Presentation
Data Provided by Refinitiv. Minimum 15 minutes delayed.
May 16, 2022
May 12, 2022
Apr 28, 2022
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
Apr 25, 2022 at 8:00 AM EDT
Apr 12, 2022 at 4:30 PM EDT
Mar 16, 2022 at 10:00 AM EDT